Chemed (NYSE:CHE) Given Sector Perform Rating at Royal Bank Of Canada

Royal Bank Of Canada reaffirmed their sector perform rating on shares of Chemed (NYSE:CHE) in a report released on Friday morning, MarketBeat reports. They currently have a $422.00 price objective on the stock, down from their previous price objective of $572.00.

Several other brokerages also recently commented on CHE. Jefferies Financial Group downgraded shares of Chemed from a “buy” rating to a “hold” rating in a research note on Thursday, January 22nd. Zacks Research raised shares of Chemed from a “strong sell” rating to a “hold” rating in a research report on Thursday, October 30th. Finally, Weiss Ratings reissued a “hold (c-)” rating on shares of Chemed in a research note on Wednesday, January 21st. Two analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $498.00.

Chemed Trading Up 3.4%

Shares of CHE stock traded up $13.51 during trading on Friday, reaching $410.14. 407,825 shares of the company’s stock traded hands, compared to its average volume of 205,571. The company has a market capitalization of $5.81 billion, a P/E ratio of 22.33, a PEG ratio of 1.93 and a beta of 0.44. The firm’s 50-day moving average is $446.06 and its 200 day moving average is $443.89. Chemed has a 1 year low of $385.00 and a 1 year high of $623.60.

Chemed (NYSE:CHE) last released its quarterly earnings data on Wednesday, February 25th. The company reported $6.42 EPS for the quarter, missing analysts’ consensus estimates of $7.02 by ($0.60). Chemed had a net margin of 10.48% and a return on equity of 24.70%. The firm had revenue of $639.34 million during the quarter, compared to the consensus estimate of $659.09 million. During the same quarter last year, the business posted $6.83 earnings per share. Chemed’s revenue was down .1% compared to the same quarter last year. Chemed has set its FY 2026 guidance at 23.250-24.250 EPS. As a group, sell-side analysts predict that Chemed will post 21.43 earnings per share for the current fiscal year.

Chemed Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 13th. Shareholders of record on Monday, February 23rd will be paid a $0.60 dividend. The ex-dividend date of this dividend is Monday, February 23rd. This represents a $2.40 dividend on an annualized basis and a yield of 0.6%. Chemed’s payout ratio is presently 12.69%.

Institutional Trading of Chemed

Several hedge funds and other institutional investors have recently bought and sold shares of CHE. Northwestern Mutual Wealth Management Co. raised its position in Chemed by 2,444,879.3% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 5,550,103 shares of the company’s stock worth $2,374,667,000 after purchasing an additional 5,549,876 shares during the period. JPMorgan Chase & Co. raised its holdings in shares of Chemed by 4.4% in the fourth quarter. JPMorgan Chase & Co. now owns 521,900 shares of the company’s stock valued at $223,301,000 after acquiring an additional 21,932 shares in the last quarter. William Blair Investment Management LLC boosted its stake in shares of Chemed by 13.6% during the third quarter. William Blair Investment Management LLC now owns 385,124 shares of the company’s stock valued at $172,435,000 after purchasing an additional 46,038 shares in the last quarter. AQR Capital Management LLC raised its position in shares of Chemed by 89.2% in the 4th quarter. AQR Capital Management LLC now owns 325,579 shares of the company’s stock worth $139,302,000 after acquiring an additional 153,469 shares in the last quarter. Finally, TD Asset Management Inc raised its holdings in Chemed by 7.5% in the fourth quarter. TD Asset Management Inc now owns 324,546 shares of the company’s stock worth $138,860,000 after purchasing an additional 22,715 shares in the last quarter. Hedge funds and other institutional investors own 95.85% of the company’s stock.

More Chemed News

Here are the key news stories impacting Chemed this week:

• Positive Sentiment: Oppenheimer lowered its price target but kept an “outperform” rating (PT cut to $500), signaling some analysts still see multi‑quarter upside despite the recent miss. Oppenheimer PT/Rating
• Neutral Sentiment: RBC reaffirmed a “sector perform” rating and set a $422 target (down from $572), reflecting a more cautious stance but not a full downgrade; this indicates mixed analyst conviction. RBC note
• Neutral Sentiment: Chemed issued FY‑2026 EPS guidance of $23.25–$24.25 (roughly in line but slightly below consensus), and said ~55% of 2026 earnings are likely back‑half weighted as it executes transition initiatives — guidance tempers but does not eliminate investor concern. Earnings release / guidance
• Neutral Sentiment: Full Q4 earnings and conference-call transcripts were posted (Seeking Alpha, Yahoo, others); these provide management commentary on margin compression, VITAS trends and cash‑flow dynamics for investors doing deeper diligence. Earnings call transcript
• Negative Sentiment: Zacks highlights the headline: Q4 EPS and revenue missed consensus, margins contracted and the FY‑2026 EPS outlook came in below street expectations — the earnings shock was the primary catalyst for the sharp share drop. Zacks: Earnings & margins miss
• Negative Sentiment: Detailed quarter metrics (QuiverQuant) show revenue and EPS declines, steeper drops in operating cash flow and lower cash balances — these raise near‑term liquidity and execution risk concerns for investors. QuiverQuant: Financial details
• Negative Sentiment: Johnson Fistel announced an investigation into possible claims tied to Chemed executives — potential litigation risk can amplify selling pressure and valuation uncertainty. GlobeNewswire: Investigation notice
• Negative Sentiment: BofA cut Chemed to neutral after the Q4 miss — another sign of weakening analyst conviction that can pressure sentiment until evidence of margin/cash‑flow stabilization appears. MSN / BofA note

Chemed Company Profile

Chemed Corporation is a diversified provider of essential home services and healthcare solutions in the United States. Headquartered in Cincinnati, Ohio, the company operates through two principal business segments—Roto-Rooter and Vitas Healthcare. Since its founding in 1974, Chemed has built a reputation for reliability and expertise, serving both residential and commercial customers across a broad range of markets.

The Roto-Rooter segment offers a comprehensive suite of plumbing, drain cleaning and water restoration services.